AirNexis launches with $200m and Phase 2 dual PDE3/4 COPD drug licensed from Haisco
AirNexis launches with $200M and ex-China rights to AN01. Find out why this dual-pathway COPD therapy is drawing investor attention in 2026.
Why Naveris’s NavDx performance outcomes could alter HPV cancer follow‑up standards
See how Naveris’s NavDx ctHPV DNA results are reshaping HPV cancer surveillance and what this means for clinicians, payers, and precision oncology adoption.
Why Revvity’s Signals Xynthetica integration with Lilly TuneLab could reshape biotech AI
Revvity and Lilly team up to scale AI-powered drug discovery. Find out how federated learning could reshape access to predictive models across biotech.
Medipost raises $140m to fund U.S. Phase III trial of stem cell therapy for knee osteoarthritis
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.
Eli Lilly taps Chai Discovery to accelerate biologics with AI-generated candidates
Eli Lilly partners with Chai Discovery to deploy AI for antibody drug design. Find out what this means for the future of biologics R&D.
Can Assertio win market traction with convenience-led G-CSF dosing schedules?
Can same-day dosing of Rolvedon reduce burden in breast cancer care? Explore new trial data, regulatory risks, and clinical impact in this detailed analysis.
MRM-3379 enters patient testing for Fragile X syndrome in Mirum’s BLOOM Phase 2 trial
MRM-3379 enters Phase 2 testing for Fragile X syndrome. Find out what this means for PDE4D inhibition, IDD drug design, and future trial direction.
PharmaJet’s needle-free system to power Scancell’s melanoma Phase 3 after strong DNA therapy data
PharmaJet’s needle-free device will deliver Scancell’s DNA immunotherapy in a Phase 3 melanoma trial. Find out what this means for the future of cancer vaccines.
Can Amneal’s Parkinson’s strategy evolve beyond symptoms? KeifeRx tie-up may signal shift
KeifeRx and Amneal join forces on KFRX06, a brain-penetrant LRRK2 inhibitor for Parkinson’s. Find out what this could mean for CNS innovation.
Amazon adds oral Wegovy to pharmacy platform: Will this reshape obesity care logistics?
Amazon Pharmacy now delivers oral Wegovy with insurance and cash-pay options. Find out how this reshapes GLP-1 access and obesity care.